In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
- Pathology Technology Australia’s key priorities in the coming years
- Current local capability in pathology technology compared to other countries
- How the health system supports change and adoption of pathology technology
- How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
- Observations in the Strengthening Medicare Taskforce Report
And lastly Dean looks towards the Federal Budget this year and in 2024 for the adoption of currently unfunded pathology tests, that could alter pathology as a cost centre to one that saves the health system considerable money.
-
Access and productivity outcomes with radiology technology in Western Sydney
In Western Sydney, there is currently significant growth accompanied by a notable need for cardiovascular support due to the prevalence of related diseases. It is estimated that the population in this area will reach 6 million by 2041.
With this population growth, there is also a pressing shortage of healthcare professionals in Australia, particularly in the field of radiology, where there are not enough radiographers, sonographers, MRI technicians, and nuclear medicine technicians.
-
NSW Medical Device Commercialisation Training Program (MDCTP) Graduation 2019
Cicada Innovations with NSW Health this week hosted the graduation night for the 15 individuals that were part of the NSW Medical Device Commercialisation Training Program (MDCTP).
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
